Abstract
Summary
In addition to producing anomalies in rats, 6-mercaptopurine and thioguanine cause a decrease in placental weight.
Other purine derivatives which produce no anomalies have no effect on placental weight. These findings suggest that a relationship exists between malformations and placental growth inhibition. Administration of 4-hydroxypyrazolo-(3,4-d)-pyrimidine (a xanthine oxidase inhibitor) with non-teratogenic dosages of 6-mercaptopurine results in anomalies and decreased placental weight. Furthermore, combination of the former drug with terato-genic dosages of the latter causes fetal death.
Get full access to this article
View all access options for this article.